liposomes

Real-time CARS microspectroscopy to follow changes of membrane associated water molecules induced by the electropulsation of liposomes

To deep more insight into basic phenomena occurring during and after electropulsation of biological membranes, a new experimental modality has been used. It combines a wide field Coherent Anti Stokes Raman Spectroscopy system with a coplanar wave guide able to deliver nanosecond pulsed electric fields to different in vitro samples. The experiments have been conducted on liposome suspensions. These systems well mimic phospholipid double layers. Spectra of liposome suspensions have been acquired immediately after electropulsation.

SPC liposomes as possible delivery systems for improving bioavailability of the natural sesquiterpene β-caryophyllene: lamellarity and drug-loading as key features for a rational drug delivery design

The natural sesquiterpene β-caryophyllene (CRY) has been highlighted to possess interesting pharmacological potentials, particularly due to its chemopreventive and analgesic properties. However, the poor solubility of this sesquiterpene in aqueous fluids can hinder its uptake into cells, resulting in inconstant responses of biological systems, thus limiting its application. Therefore, identifying a suitable pharmaceutical form for increasing CRY bioavailability represents an important requirement for exploiting its pharmacological potential.

Human biomolecular corona of Liposomal Doxorubicin: the overlooked factor in anticancer drug delivery

More than 20 years after its approval by the Food and Drug Administration (FDA), liposomal doxorubicin (DOX) is still the drug of choice for the treatment of breast cancer and other conditions such as ovarian cancer and multiple myeloma. Yet, despite the efforts, liposomal DOX did not satisfy expectations at the clinical level. When liposomal drugs enter a physiological environment, their surface gets coated by a dynamic biomolecular corona (BC).

Effect of glucose on liposome–plasma protein interactions: relevance for the physiological response of clinically approved liposomal formulations

Recently, the concept is emerging that the reduced success of nanoparticles in clinical practice is due to the adsorption of the “biomolecular corona (BC),” which alters their biological identity. Apart from protein variations, alterations in the human metabolome may change the BC decoration, which has poorly been addressed so far. Here, glucose is used as a model metabolite and how the interactions between liposomes (as a model nanoparticle) and plasma proteins are influenced by normal and diabetic sugar blood levels is explored.

Clinically approved liposomal nanomedicines: lessons learned from the biomolecular corona

Nowadays, liposomes are the most successful drug delivery systems with a dozen drug products available in the clinic. Grafting poly-(ethylene glycol) (PEG) onto the liposome surface prevents protein binding thus prolonging blood circulation, while synthetic modification of the terminal PEG molecule with ligands (e.g. monoclonal antibodies and peptides) should promote selective accumulation in the tumor region with respect to healthy tissues. However, despite big efforts, advances have not outgrown the development stage and just a few targeted liposomal drugs are commercially available.

Effect of molecular crowding on the biological identity of liposomes: an overlooked factor at the bio-nano interface

Once embedded in a physiological environment, the surface of nanoparticles (NPs) gets covered with a biomolecular corona (BC) that alters their synthetic characteristics and subsequently gives them a peculiar biological identity. Despite recent studies having clarified the role of NP composition, surface chemistry and biological source (e.g., human/animal serum or plasma) in the formation of the BC, little is known about the possible impact of molecular crowding.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma